Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 4 (5), 795-805

Resistance to Anti-Influenza Drugs: Adamantanes and Neuraminidase Inhibitors

Affiliations
Review

Resistance to Anti-Influenza Drugs: Adamantanes and Neuraminidase Inhibitors

Aeron C Hurt et al. Expert Rev Anti Infect Ther.

Abstract

Development of effective drugs for the treatment or prevention of epidemic and pandemic influenza is important in order to reduce its impact. Adamantanes and neuraminidase inhibitors are two classes of anti-influenza drugs available for influenza therapy currently. However, emergence of resistance to these drugs has been detected, which raises concerns regarding their widespread use. In this review, resistance to the adamantanes and neuraminidase inhibitors will be discussed in relation to both epidemic and pandemic influenza viruses.

Similar articles

See all similar articles

Cited by 24 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback